Vaccine Roll-out

Debate between John Howell and Matt Hancock

Thursday 21st January 2021 Commons Chamber

[John Howell (Henley) (Con) [V]]

I welcome the opening of vaccination centres across the country, including one imminently at the Kassam stadium in Oxford, but at a meeting that I attended last night of community leaders in Oxfordshire, no one had an idea of when the vaccine centre at Harwell would become operational. Could the Secretary of State oblige?

[Matt Hancock]

[Inaudible.] the date when it will open. There is a huge amount of investment going into Harwell to make sure that we have cutting-edge vaccination manufacturing facilities for the future. The project is being led by my right hon. Friend the Secretary of State for Business, Energy and Industrial Strategy, so I will write to my hon. Friend with all the details.

Covid-19 Update

Debate between John Howell and Matt Hancock

Programme motion
Monday 19th October 2020 Commons Chamber

[Matt Hancock]

Of course, no vaccine technology is certain, but the longer we go without bad news, the better things are, because we would hear if things had not gone well, so things are therefore progressing. The Joint Committee on Vaccination and Immunisation produces a prioritisation based on clinical advice and its clinical judgment on who ought to get the vaccine in what order. This is a really important question to ensure that we roll out the vaccine fairly and on an agreed basis. I will ask the Committee to look at the hon. Gentleman’s specific request to make sure that is taken into account. The Committee’s advice is very important for the Government decision that I hope the whole country can then get behind.

[John Howell (Henley) (Con)]

I make no apology for again bringing up the question of co-trimoxazole since I believe the drug can help very much in the fight against covid. Following the successful trials in India and Bangladesh, has there been any progress here?

[Matt Hancock]

My hon. Friend is right to raise that question, and I will write to him with a full update once I have taken advice from my clinical advisers and from Professor Jonathan Van-Tam, who leads on this area.

Coronavirus Response

Debate between John Howell and Matt Hancock

Monday 20th July 2020 Commons Chamber

[Matt Hancock]

The hon. Lady makes an important point, but the No. 1 cause of people not self-isolating is if they have coronavirus without symptoms and do not get a test. That is where we need the most effort. However, I hear the point that she is making, and I will take it away.

[John Howell (Henley) (Con)]

Is my right hon. Friend aware that co-trimoxazole is receiving tests against covid in Bangladesh and that the increasingly good results from there and India will be published very shortly? When are we likely to see it in use here?

[Matt Hancock]

I will immediately look into the proposal; I would be surprised if my scientists were not already across the trial. If there is a positive signal from that trial, we will make sure that we will absolutely bring it forward.

Coronavirus

Debate between John Howell and Matt Hancock

Wednesday 17th June 2020 Commons Chamber

[Matt Hancock]

I accept responsibility for everything that happens across the health and social care piece. It is incredibly important to work with care homes, as we have, and to fund care homes, as we have, to put in place infection control. Of course, being in hospital is also not a safe place for people who do not need to be in hospital. The infection control procedures are now there in care homes, with the funding, and that has been the case since the start—since well before the date the hon. Lady mentioned. Although the challenge in care homes has been very significant, we have thankfully seen in this country a lower proportion of overall fatalities from this disease in our care homes than in those across the rest of Europe. That is a good thing, but that is not to say that there have not been significant challenges.

[John Howell (Henley) (Con)]

What further examination of the potential use of co-trimoxazole has taken place, and when will we know the results?

[Matt Hancock]

Co-trimoxazole is another the prospect that we are looking at, but I am afraid that, as with my answer to my right hon. Friend the Member for Wokingham (John Redwood), the timing has to be driven by the science. If we get success, when a result in which the clinicians have scientific confidence can be met, we will stick with the clinical trial methodology that leads to concrete results. Too many other places around the world have pulled clinical trials early because of promising results that have turned out not to be well founded.

Eurotunnel: Payment

Debate between John Howell and Matt Hancock

Monday 4th March 2019 Commons Chamber

[John Howell (Henley) (Con)]

The Secretary of State has talked about medicines, but there are also prescribed foods—for example, the gluten-free food on which some people depend. What will the situation be for those foods?

[Matt Hancock]

Of course that matters enormously, too. Although medicines are the category 1 prioritised goods that will be using the extra procured capacity safeguarded by this settlement, there are other measures being undertaken by the Department for Environment, Food and Rural Affairs to protect the supply of foods.

Mental Capacity (Amendment) Bill [Lords]

Debate between John Howell and Matt Hancock

2nd reading: House of Commons & Money resolution: House of Commons & Programme motion: House of Commons & Ways and Means resolution: House of Commons
Tuesday 18th December 2018 Commons Chamber

[Matt Hancock]

I have had some discussions on that subject, and I am happy for the hon. Lady to take up that point in more detail either directly with me or with the Minister for Care, or in Committee, because there are significant interlinkages between the two areas.

The Bill builds on the extensive work and recommendations of the Law Commission. It has been fully scrutinised by the Joint Committee on Human Rights and then improved by the other place, as has been discussed. I am grateful for all that work. Ultimately, it is about striking a balance between liberty and protection.

[John Howell (Henley) (Con)]

My right hon. Friend mentions the Law Commission and its suggestions. What he proposes does not quite tally with all the Law Commission’s recommendations. Where are the differences?

[Matt Hancock]

We built the Bill on the basis of the Law Commission report, but we have put some differences into the Bill. For instance, we think the principle of prioritising people over process is important, and we have strengthened that compared with the Law Commission’s recommendations. The Law Commission improves the law but does not make policy decisions. On top of the Law Commission’s work, which is incredibly helpful, we have made further policy decisions to ensure that people are put more foursquare at the heart of the process. It is true that the Bill and the Law Commission’s recommendations are not exactly aligned, but I would strongly defend our further improvements.

Prevention of Ill Health: Government Vision

Debate between John Howell and Matt Hancock

Monday 5th November 2018 Commons Chamber

[Matt Hancock]

I have of course looked at that report. It is important, and it is important that we get the answers to it right.

[John Howell (Henley) (Con)]

Will the Secretary of State agree that more education should be spent on understanding the total role of sugars in combating diabetes, to go with the success that he has had with regards to the direct focus on sugars in drinks and food?

[Matt Hancock]

My hon. Friend is absolutely right; I strongly agree. Reformulation is critical. However, it is crucial to look not just at sugar, but at calorie count. Replacing sugars with higher calorie products is not necessarily the right way forward.

Small Business, Enterprise and Employment Bill

Debate between John Howell and Matt Hancock

Tuesday 24th March 2015 Commons Chamber

[Matthew Hancock]

With only a few days remaining in this Parliament, the Government continue to work tirelessly to make the UK the best place in the world to start and grow a business. We are proud of our record over this Parliament, including the 760,000 extra businesses, the 2.2 million extra jobs that business has created and the rising pay that has benefited millions. This has been possible only because of our unstinting and unambiguous support for businesses. Last week’s Budget built on this record with a fundamental review of business rates, and last week we set out our intentions for using the new prompt payment transparency powers. The Bill takes this commitment to support small business further. It is the first ever small business Bill and I hope will shortly become the first ever small business Act.

In the other place, the Bill was, as we would expect, subjected to careful and robust scrutiny, and I am grateful to Baroness Neville-Rolfe for ably steering it through the other place, where it was enhanced and improved. As part of that, several amendments were made, both substantive and technical. The Government supported all the successful amendments, and I hope that the House will agree them today. I shall go through each in turn, beginning with late payment. The Bill takes unprecedented steps to tackle late payment, so understandably the matter was debated in detail in this House and the other place. Late payment is a major issue for businesses large and small, and we are taking steps in the Bill and elsewhere to bring an end to the UK’s late payment culture once and for all.

Transparency has a pivotal role to play. Clause 3 introduces a tough new prompt payment reporting requirement for the UK’s largest companies. In the other place, this clause was further strengthened by amendments 1 to 3, which insert a reference to performance on the face of the Bill and make express reference to late payment interest as an example of the type of information that will be included in the report. Beyond the Bill, we have strengthened the prompt payment code with our announcement last month that 30-day payment terms will be the norm of acceptable behaviour, with 60 days as the maximum in all but exceptional circumstances.  The public sector will play its part, as 30-day terms are now legally required right down the public sector supply chain.

The transparency measures in the Bill will shine a light on poor payment practices and make a company’s payment terms a reputational boardroom issue. We will drive a culture change to redress the current economic imbalance of power between large companies and their suppliers. The amendments under consideration today will help to ensure suppliers are fairly compensated. We are determined to make 30-day terms the norm and 60 days the maximum acceptable payment terms. With this Bill, we will make unacceptable late payment a thing of the past.

[John Howell (Henley) (Con)]

I very much welcome what the Minister said and I welcome the clause. When I was running a small business of my own, late payments bedevilled the business, and it was always the larger companies that were responsible for it. I am very glad that this amendment is being made.

[Matthew Hancock]

I am grateful for that intervention. I, too, have personal experience of poor payment performance having a massive impact on the businesses I worked in. Frankly, the late payment culture is a problem with our contract law. Good contract law means good payment against a contract. I think these transparency measures will have a significant impact, changing prompt payment from being an issue for finance directors to being an issue for the board. Through these transparency measures, we will not allow it to be deemed reasonable to pay late. I think that 60 days as a maximum and 30 days as a norm is a perfectly reasonable place to settle.

Enterprise and Regulatory Reform Bill

Debate between John Howell and Matt Hancock

Tuesday 16th October 2012 Commons Chamber

[Matthew Hancock]

I assure the hon. Gentleman that if there is under-compliance, people will have been negligent and the full force of both the criminal and civil law will be available.

The hon. Member for Hartlepool (Mr Wright) mentioned the Federation of Small Businesses, but it has stated:

“A wider problem for small businesses is that many do not feel confident that they are compliant owing to confusion about what is absolutely necessary, and so feel the need to gold-plate the law to protect them.”

Indeed, an FSB survey showed that 87% of its members supported the Löfstedt approach. Given that figure, and given that the FSB is clear about the lack of confidence caused by the current confusion in the law, I hope he will accept that it is very much behind the Government’s approach.

Likewise, EEF, the manufacturers’ organisation, has stated:

“The current compensation system is serving the needs of neither employees nor employers and is the source of many of the media stories and public concern about excessive health and safety.”

That concern has been part of our debate. Of course, the substance of when technical breaches occur is a crucial part of the change that we are making, but I am glad that the hon. Gentleman acknowledged that there is also the problem of perception, which leads to over-complication. Both those problems need to be addressed, and they will be by our changes.

[John Howell (Henley) (Con)]

I was moved, as I am sure everyone else in the House was, by the earnest statements that Opposition Members made about how members of their families and other people they knew had been killed by industrial diseases. However, difficulties such as those that we find in the current legislation do not help to prevent such cases.